Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 1997

View Archived Issues

StressGen and Genzyme announce closing of joint venture

PLC Systems faces class action suits

Pharmacia Biotech and Amersham Life Science merger finalized

Study confirms hepatitis B vaccine efficacy

GABA-based drug for anxiety enters phase I

PLC responds to nonapproval of its Heart Laser TMR System

New HRT option from Organon

Dietary changes may pose threat to patients on oral anticoagulants

Matrix and Savage enter marketing agreement for AccuSite

Medtronic's therapy for urinary incontinence recommended for approval by FDA panel

Update on Proleukin regulatory status; Photofrin approved in Germany

First approval for Elan's Diastat

SKB reports new agents for atherosclerosis

Protein kinase C inhibitors discovered at Cephalon

Theratechnologies: Q2 1997 highlights

Aquila issued patent covering potent drug delivery agents

Tacrine analogs reported for Alzheimer's disease

Antiarthritic activity of British Biotech MMP/TNF-alpha inhibitors

Vanadium compounds for treatment of diabetes

AmBisome approved in Korea

Cantab: Q2 1997 highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...